摘要
目的分析华蟾素胶囊联合化疗治疗晚期肺癌患者的临床价值。方法在2013年11月至2014年11月,收集陕西中医药大学附属医院晚期肺癌患者的临床资料100例。并且随机数字表法分配为试验组与对照组各50例,试验组华蟾素胶囊联合化疗,对照组给予单纯化疗。2组患者在年龄、体质量、病程等方面差异无统计学意义(P>0.05)。结果华蟾素胶囊联合化疗治疗晚期肺癌患者的总体有效率达到了36%,单纯接受化疗治疗的总体有效率为30%。结论华蟾素胶囊联合化疗治疗晚期肺癌患者的临床价值比较好,能够有效改善临床的些许症状。
Objective To analyze the clinical value of cinobufotalin capsule and chemotherapy in the treatment of patients with advanced lung cancer. Methods The clinical data of 100 patients with advanced lung cancer, who were hospitalized in the Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine between November2013 and November 2014, were collected and randomly divided into the experimental group and the control group.The experimental group（n=50） received cinobufotalin capsule and chemotherapy. The control group（n=50） received chemotherapy alone. There were no statistically significant differences in age, weight and course of disease between the two groups（P〉0.05）. Results The total effective rate of cinobufotalin capsule and chemotherapy in the treatment of patients with advanced lung cancer reached 36%, whereas the total effective rate of chemotherapy alone was 30%.Conclusion The clinical value of cinobufotalin capsule and chemotherapy in the treatment of patients with advanced lung cancer is better, which can effectively improve some clinical symptoms.
出处
《中国药物与临床》
CAS
2016年第10期1406-1408,共3页
Chinese Remedies & Clinics
基金
河南省医学科技攻关计划项目(201303033)
关键词
肺肿瘤
华蟾素胶囊
抗肿瘤联合化疗方案
治疗
临床研究性
Lung neoplasms
Cinobufotalin capsule
Antineoplastic combined chemotherapy protocols
Therapies
inrestigation
